Feb. 2 at 11:44 AM
$IDXX Idexx Laboratories reports Q4 EPS
$3.08, consensus
$2.94
Reports Q4 revenue
$1.09B, consensus
$1.07B. "IDEXX delivered a strong finish to 2025, supported by consistently high levels of execution by IDEXX teams around the world," said Jay Mazelsky, President and Chief Executive Officer. "2025 was a pivotal year for the Company, marked by the successful launch of IDEXX Cancer Dx(TM) for canine lymphoma and meaningful adoption of IDEXX inVue Dx well ahead of our initial goals. These innovations represent an important new phase of IDEXX's growth, expanding the role of diagnostics in earlier disease detection while helping veterinarians improve efficiency and manage workflow complexity. We enter 2026 with an exciting innovation pipeline, expanding instrument and software installed bases, and strong momentum across our global business."
Idexx Laboratories sees FY26 EPS
$14.29-
$14.80, consensus
$14.45
Sees FY26 revenue
$4.632B-
$4.72B, consensus
$4.66B. The company's initial 2026 revenue guidance range of
$4.632B-
$4.72B, or reported growth of 7.6%-9.6% and 7.0%-9.0% on an organic basis, is supported by 8.6% - 10.6% reported and 8.0%-10.0% organic CAG Diagnostics recurring revenue growth. The guidance range for global CAG Diagnostics recurring revenue growth reflects expectations for sustained benefits from execution drivers, supporting continued solid volume gains, and an estimated 4% full-year benefit from net price improvement. 2026 EPS guidance of
$14.29-
$14.80 reflects expectations for solid organic revenue gains and a targeted 40-90 basis points of reported operating margin improvement.
